Activation of ERK/IER3/PP2A-B56γ-positive feedback loop in lung adenocarcinoma by allelic deletion of B56γ gene.

In order to investigate the involvement of the IER3/PP2A-B56γ/ERK-positive feedback loop, which leads to sustained phosphorylation/activation of ERK in carcinogenesis, we immunohistochemically examined the expression of IER3 and phosphorylated ERK in lung tumor tissues. IER3 was overexpressed in all cases of adenocarcinomas examined, but was not overexpressed in squamous cell carcinomas. Phosphorylated ERK (pERK) was also overexpressed in almost all adenocarcinomas. EGFR and RAS, whose gene product is located upstream of ERK, were sequenced. Activating mutation of EGFR, which is a possible cause of overexpression of IER3 and pERK, was found only in 5 adenocarcinomas (42%). No mutation of RAS was found. We further examined the sequences of all exons of B56γ gene (PPP2R5C) and IER3, but no mutation was found. Using a single nucleotide insertion in intron 1 of PPP2R5C, which was found in the process of sequencing, allelic deletion of PPP2R5C was examined. Eight cases were informative (67%), and the deletion was found in 4 of them (50%). Three cases having deletion of PPP2R5C did not have EGFR mutation. Finally, PPP2R5C deletion or EGFR mutation that could be responsible for IER3/pERK overexpression was found in at least 8 cases (67% or more). This is the first report of a high incidence of deletion of PPP2R5C in human carcinomas.

[1]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[2]  C. Marshall,et al.  Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation , 1995, Cell.

[3]  Yigong Shi Serine/Threonine Phosphatases: Mechanism through Structure , 2009, Cell.

[4]  A. Arlt,et al.  Role of the immediate early response 3 (IER3) gene in cellular stress response, inflammation and tumorigenesis. , 2011, European journal of cell biology.

[5]  J. Minna,et al.  Alterations of the PPP2R1B gene in human lung and colon cancer. , 1998, Science.

[6]  F. Porteu,et al.  IEX‐1: a new ERK substrate involved in both ERK survival activity and ERK activation , 2002, The EMBO journal.

[7]  S. Artan,et al.  Detection of deletions and/or amplifications of genes related with lung cancer by multiplex ligation-dependent probe amplification (MLPA) technique , 2009, Cancer biology & therapy.

[8]  A. Vincent-Salomon,et al.  Loss of heterozygosity at 13q13 and 14q32 predicts BRCA2 inactivation in luminal breast carcinomas , 2013, International journal of cancer.

[9]  Wu Mx Roles of the stress-induced gene IEX-1 in regulation of cell death and oncogenesis. , 2003 .

[10]  R. Tomasini,et al.  IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation. , 2014, The Journal of clinical investigation.

[11]  V. Band,et al.  The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants# , 2009, Oncogene.

[12]  M. Jung,et al.  Identification and characterization of a radiation-inducible glycosylated human early-response gene. , 1996, Cancer research.

[13]  Yoo Jin Jung,et al.  The transcriptional landscape and mutational profile of lung adenocarcinoma , 2012, Genome research.

[14]  C. van Hoof,et al.  PP2A: the expected tumor suppressor. , 2005, Current opinion in genetics & development.

[15]  W. Hahn,et al.  Multiple pathways regulated by the tumor suppressor PP2A in transformation. , 2008, Trends in molecular medicine.

[16]  Chung-Liang Ho,et al.  Allelic loss of 14q32 in the pathogenesis of gastrointestinal and ampullary malignancies: mapping of the target region to a 17 cM interval , 2005, Journal of Cancer Research and Clinical Oncology.

[17]  Takashi Takahashi,et al.  Loss of heterozygosity (LOH) at 17q and 14q in human lung cancers , 1998, Oncogene.

[18]  Mei X. Wu,et al.  Clinical Significance of IEX-1 Expression in Ovarian Carcinoma , 2011, Ultrastructural pathology.

[19]  M. Zorzetto,et al.  EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells , 2013, Journal of Cancer Research and Clinical Oncology.

[20]  D. Ribatti,et al.  Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma , 2009, Clinical Cancer Research.

[21]  A. Zentella,et al.  Protein phosphatase 2A is essential to maintain active Wnt signaling and its Aβ tumor suppressor subunit is not expressed in colon cancer cells , 2015, Molecular carcinogenesis.

[22]  Shaohua Chen,et al.  Expression and distribution of PPP2R5C gene in leukemia , 2011, Journal of hematology & oncology.

[23]  M. Lung,et al.  Genetic alterations detected on chromosomes 13 and 14 in Chinese non-small cell lung carcinomas. , 2003, Cancer letters.

[24]  Mei X. Wu,et al.  Immediate early response gene X-1, a potential prognostic biomarker in cancers , 2013, Expert opinion on therapeutic targets.

[25]  J. Keats,et al.  Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes. , 2009, Cancer research.

[26]  Y. Tesfaigzi,et al.  How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? , 2009, Cell cycle.

[27]  V. Janssens,et al.  Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. , 2001, The Biochemical journal.

[28]  M. Isobe,et al.  Loss of heterozygosity of 14q32 in colorectal carcinoma. , 1999, Cancer genetics and cytogenetics.

[29]  A. Al-Hakim,et al.  Metastatic recurrence of early-stage colorectal cancer is linked to loss of heterozygosity on chromosomes 4 and 14q , 2006, Journal of Clinical Pathology.

[30]  P. Cohen,et al.  Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. , 1992, The Biochemical journal.

[31]  M. Isobe,et al.  Allelic imbalance of 14q32 in esophageal carcinoma. , 2002, Cancer genetics and cytogenetics.

[32]  Y. Kaneko,et al.  Deletion mapping of 14q32 in human neuroblastoma defines an 1,100-kb region of common allelic loss. , 2000, Medical and pediatric oncology.

[33]  K. Azuma,et al.  Prognostic Significance of the Immediate Early Response Gene X-1 (IEX-1) Expression in Pancreatic Cancer , 2008, Annals of Surgical Oncology.

[34]  J. Hecht,et al.  Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Minna,et al.  Progress in understanding the molecular pathogenesis of human lung cancer. , 1998, Biochimica et biophysica acta.

[36]  F. Porteu,et al.  B56‐containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX‐1 and ERK , 2006, The EMBO journal.

[37]  C. Croce,et al.  Loss of heterozygosity at chromosome 11q in lung adenocarcinoma: identification of three independent regions. , 1995, Cancer research.

[38]  Cheng-Wei Wu,et al.  The B56γ3 Regulatory Subunit of Protein Phosphatase 2A (PP2A) Regulates S Phase-specific Nuclear Accumulation of PP2A and the G1 to S Transition* , 2010, The Journal of Biological Chemistry.

[39]  Rony Seger,et al.  The ERK Cascade: Distinct Functions within Various Subcellular Organelles. , 2011, Genes & cancer.

[40]  J. Settleman,et al.  Targeting the RAF-MEK-ERK pathway in cancer therapy. , 2009, Cancer letters.

[41]  R. Trojanec,et al.  Non-small cell lung cancer--genetic predictors. , 2013, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[42]  T. Shioda,et al.  Identification of cyclin D1- and estrogen-regulated genes contributing to breast carcinogenesis and progression. , 2006, Cancer research.

[43]  L. Lau,et al.  Genomic structure, cDNA sequence, and expression of gly96, a growth factor-inducible immediate-early gene encoding a short-lived glycosylated protein. , 1993, Oncogene.

[44]  R. Bernards,et al.  Protein phosphatase 2A regulatory subunits and cancer. , 2009, Biochimica et biophysica acta.

[45]  Y. Ishikawa,et al.  Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations. , 2010, Lung cancer.

[46]  P. Validire,et al.  Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features. , 2005, Lung cancer.

[47]  Xuan Liu,et al.  B56γ Tumor-Associated Mutations Provide New Mechanisms for B56γ-PP2A Tumor Suppressor Activity , 2013, Molecular Cancer Research.

[48]  H Nojima,et al.  A truncated isoform of the PP2A B56 subunit promotes cell motility through paxillin phosphorylation , 2000, The EMBO journal.

[49]  H. Sakurai,et al.  Dynamic Regulation of Extracellular Signal-Regulated Kinase (ERK) by Protein Phosphatase 2A Regulatory Subunit B56γ1 in Nuclei Induces Cell Migration , 2013, PloS one.